A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community: The Framingham Heart Study

JAMA

Volumn 290, Issue 8, 2003, Pages 1049-1056

  Wang, Thomas J ^a,b   Massaro, Joseph M ^a,c   Levy, Daniel ^a,b,d,e   Vasan, Ramachandran S ^a,e   Wolf, Philip A ^a,e   D'Agostino, Ralph B ^a,c,e   Larson, Martin G ^a   Kannel, William B ^a,e   Benjamin, Emelia J ^a,e  

^a FRAMINGHAM HEART STUDY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Boston University   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; INSULIN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EXAMINATION; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; ONSET AGE; PATIENT COUNSELING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING; UNITED STATES; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL ANALYSIS; WARFARIN;

EID: 0042422040     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.8.1049     Document Type: Article

References (44)

1. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update., Dallas, Tex: American Heart Association; 2002.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
3. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973-977.
4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
6. SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with non-valvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA. 1998;279:1273-1277.
7. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med. 1992;116:1-5.
8. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
9. van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163:936-943.
10. Hart RG, Halperin JL. Atrial fibrilation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-695.
11. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med. 2001;161:1443-1447.
12. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-2448.
13. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
14. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
15. Lake FR, Cullen KJ, de Klerk NH, et al. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med. 1989;19:321-326.
16. Onundarson PT, Thorgeirsson G, Jonmundsson E, et al. Chronic atrial fibrillation-epidemiologic features and 14 year follow-up: a case control study. Eur Heart J. 1987;8:521-527.
17. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health. 1951;41:279-286.
18. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
19. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram; prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med. 1969;71:89-105.
20. Hart RG, Pearce LA, McBride R, et al, for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAFI-III clinical trials. Stroke. 1999;30:1223-1229.
21. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
22. Sullivan LM, Massaro MM, D'Agostino RB. Presentation of multivariate data for clinical use: the Framingham Risk Score Functions. Stat Med. In press.
23. Nam BH, Discrimination and Calibration in Survival Analysis [dissertation]. Boston, Mass: Boston University; 2000.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
25. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114 (suppl 5):579S-589S.
26. Cabin HS, Clubb KS, Hall C, et al. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol. 1990;65:1112-1116.
27. Novello P, Ajmar G, Bianchini D, et al. Ischemic stroke and atrial fibrillation: a clinical study. Ital J Neurol Sci. 1993;14:571-576.
28. Feinberg WM, Macy E, Cornell ES, et al, for the Stroke Prevention in Atrial Fibrillation Investigators. Plasmin-alpha2-antiplasmin complex in patients with atrial fibrillation. Thromb Haemost. 1999;82:100-103.
29. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 2002;39:739-743.
30. Feinberg WM, Kronmal RA, Newman AB, et al. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med. 1999;14:56-59.
31. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187.
32. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-2037.
33. Pearce LA, Hart RG, Halpedn JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000;109:45-51.
34. Fihn SD, Callahan CM, Martin DC, et al, for the National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970-979.
35. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: echocardiographic features of patients at risk. Ann Intern Med. 1992;116:6-12.
36. Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke. 1999;30:1218-1222.
37. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158:1316-1320.
38. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patents with atrial fibrillation: executive summary. J Am Coll Cardiol. 2001;38:1231-1266.
39. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
40. Hart RG, Pearce LA, Rothbart RM, et al, for the Stroke Prevention in Atrial Fibrillation Investigators. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183-187.
41. Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol. 1998;82:580-583.
42. Wood KA, Eisenberg SJ, Kalman JM, et al. Risk of thromboembolism in chronic atrial flutter. Am J Cardiol. 1997;79:1043-1047.
43. Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87:346-349.
44. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.